Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Meiji’s Stelara Biosimilar Shows Therapeutic Equivalence; Filing Eyed in 2023
January 23, 2023
- CSL Behring Launches App to Manage Hizentra Treatment Records
January 20, 2023
- Eisai Starts Stand-Alone Biz Operations in Israel
January 20, 2023
- Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Shionogi Commences New COVID Vaccine Trials for Children
January 18, 2023
- Chiome, China Firm Call off License Deal for Anti-TROP-2 Antibodies
January 18, 2023
- Chugai to End Sale of Joint Function Improving Agent Suvenyl in Japan
January 17, 2023
- Towa Set to Take on Legal Battle over Treakisym Patent
January 17, 2023
- Toray Rolls Out Remitch OD Tablets in South Korea
January 17, 2023
- Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Estimated 11,867 Patients Given Xocova as of Jan. 5: Shionogi
January 16, 2023
- Ono, Monash University Ink GPCR Antibody Deal
January 16, 2023
- Skyrizi’s New IV Form Now Available for Crohn’s Disease
January 16, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- Takeda’s Exkivity Approved in China for EGFR Exon 20+ NSCLC
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
- Zeria’s Acinon Now Sole Nizatidine Product Being Shipped as Yoshindo Launches Recall
January 13, 2023
- Janssen Vows to Offer New Positions for Employees Shown Exit Door: 1st Labor Talks
January 13, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…